NCT04635735View on ClinicalTrials.gov

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 12, 2020

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

Ipilimumab

Ipilimumab 3 mg/kg every 3 weeks for 4 doses.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04635735 - Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter